华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 2024年度募集资金存放和使用情况专项核查报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关规定，华 泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作为爱尔眼科 医院集团股份有限公司（以下简称"爱尔眼科"、"公司"）向特定对象发行股票的保 荐机构，对爱尔眼科在 2024 年度募集资金存放与使用情况进行了核查，核查情况如 下： 一、募集资金基本情况 （一）募集资金到位情况 1、2017 年非公开发行股票募集资金到位情况 2、2021 年向特定对象发行股票募集资金到位情况 根据中国证券监督管理委员会出具的《关于同意爱尔眼科医院集团股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2022〕1704 号），并经深圳证券交 易所同意，公司于 2022 年 9 月 20 日向 14 名特定投资者以非公开发行的方式发行 人民币普通股 133,467,485 股，每股面值为人民币 1 元，发行价格为每股人民币 26.49 1 元，募集资金总额计 ...

关于爱尔眼科医院集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2025)0100512 号 爱尔眼科医院集团股份有限公司全体股东： 喻友志 我们接受委托，在审计了爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科医院集 团"）2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及 公司的现金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的 《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇 总表"）进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合 法、完整的审核证据是爱尔眼科医院集团公司管理层的责任，我们的责任是在执行审核工作 的基础上对汇总表发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计师审计准 则要求我们遵守中国注册会计师职业道德守则，计划和执行审核工作以对汇总表是否不存在 重大错报获取合理保证。在审核过程中，我们实 ...

华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 2024年度证券投资情况的核查意见 针对金融衍生品交易的内控管理情况如下： 1、公司财务管理中心负责金融衍生品交易的具体操作办理，进行交易前的 风险评估，分析交易的可行性及必要性，当市场发生重大变化时及时上报风险评 估变化情况并提出可行的应急止损措施。 2、在进行金融衍生品交易前，在多个市场与多种产品之间进行比较分析， 选择最适合公司业务背景、流动性强、风险较可控的金融衍生工具开展业务，并 选择具有合法资质和资金实力的大型银行等金融机构开展业务。 3、预先确定风险应对预案及决策机制，专人负责跟踪衍生品公允价值的变 化，及时评估已交易衍生品的风险敞口变化情况，定期汇报。在市场波动剧烈或 风险增大的情况下，增加汇报频次，确保风险预案得以及时启动并执行。 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》《深圳证券 交易所创业板上市公司自律监管指南第1号——业务办理》等相关规定，华泰联 合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作为爱尔眼科 医院集团股份有限 ...

内部控制审计报告 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，爱尔眼科股份有限公司于 2024 年 12 月 31 日按照《企业内部控制基本规范》 和相关规定在所有重大方面保持了有效的财务报告内部控制。 众环审字(2025)0100863 号 爱尔眼科医院集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了爱 尔眼科医院集团股份有限公司（以下简称"爱尔眼科公司"）2024 年 12 月 31 日的财务报告 内部控制的有效性。 一、爱尔眼科公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是爱尔眼科公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 ...

Financial Performance - The company plans to distribute a cash dividend of 1.6 yuan per 10 shares (including tax) based on a total share capital of 9,295,651,317 shares after deducting the number of shares in the repurchase account[4]. - Revenue for the last quarter reached 1.2 billion yuan, marking a 15% increase compared to the previous quarter[19]. - The company reported a significant increase in user data, with a total of 150,000 new patients treated in the last quarter, representing a 25% year-over-year growth[18]. - The company anticipates a positive growth trajectory, with revenue projections indicating a robust performance in the upcoming fiscal year[17]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter, showcasing improved operational efficiency[22]. - The company's operating revenue for 2024 reached approximately RMB 20.98 billion, representing a 3.02% increase compared to RMB 20.37 billion in 2023[30]. - Net profit attributable to shareholders for 2024 was approximately RMB 3.56 billion, up 5.87% from RMB 3.36 billion in 2023[30]. - The company has set a performance guidance of 1.5 billion RMB in revenue for the next quarter, representing a 25% growth target[21]. Market Expansion and Acquisitions - The company plans to expand its market presence by opening 10 new hospitals in the next fiscal year, targeting regions with high demand for eye care services[19]. - The company successfully completed the acquisition of two regional eye hospitals, which is expected to contribute an additional 300 million yuan in annual revenue[19]. - A strategic acquisition of a regional competitor is anticipated to be finalized by Q2 2024, which is expected to increase market share by 10%[20]. - The company has completed multiple acquisitions, enhancing its market presence in the medical sector[105]. - The company plans to continue its strategy of acquiring eye hospitals to enhance its service network and market share in the healthcare sector[112]. - The company completed acquisitions of multiple eye hospitals, including a 51% stake in Nanjing Aier Anxing Eye Hospital for 89.35 million and a 51% stake in Xupu Aier Eye Hospital for 93.23 million[109]. - The company has established partnerships with local medical investment firms to facilitate future growth and operational efficiency[110]. Technological Advancements - The company is focused on technological advancements in eye care, investing in new equipment and training for staff to improve patient outcomes[16]. - The company is exploring partnerships with technology firms to integrate AI in patient diagnostics, which could reduce diagnosis time by 30%[19]. - The company launched the AierGPT model in September 2024, enhancing eye health education, diagnosis, training, and management[48]. - The company is developing a federated general large model for ophthalmology, aiming to serve over 10,000 patients across more than 50 hospitals, enhancing clinical research capabilities[85]. - The company is focusing on integrating AI-driven digital human services for pre-, in-, and post-operative care, aiming to improve the quality of ophthalmic services[85]. Operational Efficiency and Quality Management - The company is committed to maintaining high standards of care, which is expected to drive patient satisfaction and retention[17]. - The company has established a medical quality management committee to enhance the quality and safety of medical services, implementing a three-year plan for development direction and key work[52]. - The company has achieved a patient complaint response rate of 100% and a resolution completion rate of 98%[54]. - The company has implemented a comprehensive training program, conducting 35 strategic training sessions to enhance the skills of its medical staff[50]. - The company has developed a trademark licensing management system to regulate the use of its brand and ensure compliance among authorized hospitals[164]. Research and Development - The company has invested 200 million yuan in research and development for innovative eye care technologies, aiming to enhance treatment outcomes[19]. - The company is advancing a federated learning model for ophthalmology, supporting at least 20 common eye diseases, with performance improvements of over 30% compared to local models[83]. - The company is focusing on the development of anti-aging drugs for age-related macular degeneration (AMD), with several effective candidates identified[89]. - The company has approved 73 vertical research projects during the reporting period, including 5 national-level projects and 55 provincial-level projects[56]. - The company aims to publish high-level scientific papers and apply for multiple patents to support its research initiatives[87]. Strategic Partnerships and Collaborations - The company is exploring strategic partnerships to leverage synergies and improve operational efficiencies[16]. - The company has formed strategic partnerships with 16 well-known universities to deepen cooperation in talent training and academic research[57]. - The company established a strategic cooperation framework with iFlytek to explore broader applications of AI in ophthalmology, promoting digital eye health services[48]. - The company is focusing on integrating global resources to enhance clinical, educational, and research capabilities, thereby improving its industry position[45]. Governance and Management - The company is focused on maintaining strong governance practices, as evidenced by the approval of several internal management systems[182]. - The company has a diverse board of directors, including independent directors with varying backgrounds and expertise[185]. - The company emphasizes compliance and governance, with board members holding various professional qualifications, including CPA and tax advisor certifications[189]. - The company is committed to enhancing investor relations, as evidenced by the recognition received by Wu Shijun, the Deputy General Manager and Secretary of the Board, for excellence in investor communication[188]. Future Outlook - Future outlook includes plans for further market expansion and potential acquisitions to strengthen its market position[17]. - The company remains optimistic about its growth trajectory, with a focus on expanding its footprint in underserved markets[19]. - The company anticipates continued growth and expansion in the upcoming fiscal year[108]. - The company aims to enhance its service offerings through the integration of advanced medical technologies in its newly acquired facilities[110].

Financial Performance - The company's revenue for Q1 2025 reached ¥6,026,140,250.98, representing a 15.97% increase compared to ¥5,196,134,001.26 in the same period last year[4] - Net profit attributable to shareholders was ¥1,049,755,960.40, up 16.71% from ¥899,476,291.54 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥1,060,021,212.23, reflecting a 25.78% increase from ¥842,752,224.61 in the previous year[4] - The total operating revenue for the current period reached ¥6,026,140,250.98, an increase of 15.9% compared to ¥5,196,134,001.26 in the previous period[19] - The net profit for the current period was ¥1,166,518,961.07, representing a growth of 20% from ¥972,413,908.00 in the previous period[20] Cash Flow - The net cash flow from operating activities increased by 41.04% to ¥1,820,785,553.45, compared to ¥1,290,939,304.47 in the same quarter last year[4] - Cash inflow from operating activities totaled $5,925,050,230.60, an increase of 12.7% compared to $5,256,300,803.12 in the previous period[23] - Cash inflow from investment activities was $136,567,500.65, significantly higher than $14,369,609.29 in the previous period[24] - The net increase in cash and cash equivalents was $848,009,119.70, compared to an increase of $540,381,588.54 in the prior period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥34,584,514,506.23, a 4.00% increase from ¥33,255,307,267.70 at the end of the previous year[4] - The total liabilities rose to ¥11,517,307,301.56, up from ¥11,443,294,269.98, indicating a slight increase of 0.65%[18] - The total current assets increased to CNY 10,821,255,475.95 from CNY 9,666,106,195.29, reflecting a growth of approximately 11.93%[16] Shareholder Equity - The equity attributable to shareholders increased by 5.43% to ¥21,839,804,852.20 from ¥20,714,588,364.92 at the end of the previous year[4] - The equity attributable to the parent company reached ¥21,839,804,852.20, an increase of 5.4% from ¥20,714,588,364.92[18] - The basic earnings per share rose to ¥0.1136, a 16.39% increase from ¥0.0976 in the same period last year[4] - The diluted earnings per share also increased by 16.87% to ¥0.1136 from ¥0.0972 year-on-year[4] Operational Efficiency - The company reported a significant increase in cash flow, indicating improved operational efficiency and financial health[4] - The weighted average return on equity was 4.93%, up from 4.67% in the previous year[4] - The total operating costs amounted to ¥4,570,692,763.37, up 13.7% from ¥4,021,509,579.51 in the prior period[19] Investments and R&D - The company has invested in intangible assets totaling ¥999,230,134.45, up from ¥860,585,187.85, indicating a focus on technology and innovation[18] - The company’s research and development expenses for the current period were ¥78,772,510.94, slightly higher than ¥74,654,886.82 in the previous period, reflecting ongoing investment in new technologies[19] - The company plans to continue expanding its market presence and investing in new technologies and products[12] Shareholder Information - The total number of shares held by the top 10 shareholders includes 3,202,323,587 shares held by the controlling shareholder, representing 79.99% of the total shares[12] - The total number of restricted shares at the end of the period is 1,396,055,322, with no changes during the current period[14] - The company’s actual controller holds 360,947,973 shares, which is approximately 10.00% of the total shares[12] - The company has a strategy to unlock 25% of the restricted shares annually based on the previous year's holdings[14]

爱尔眼科医院集团股份有限公司 独立董事2024 年年度述职报告 独立董事 2024 年年度述职报告 高国垒 本人作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"或"公司"） 的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章的规定和要 求，在 2024 年工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认 真审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事 及各专门委员会的作用。现向董事会和股东大会提交 2024 年年度述职报告，对 履行职责的情况进行说明，请予审查。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人高国垒，上海章和投资有限公司董事长。美国哥伦比亚大学高级访问学 者，复旦大学国际金融学院职业导师、EMBA 入学复试考官，上海市欧美同学会 （上海市留学人员联合会）理事，上海市创新创业大赛暨创新资金评审专家，开 能健康科技集团股份有限公司合伙人、原副总裁及董事会秘书，入选国务院发展 研究中心之"上市公司年 ...

爱尔眼科医院集团股份有限公司董事会 2025 年 4 月 24 日 爱尔眼科医院集团股份有限公司（以下简称"公司"）董事会根据《上市公司 独立董事管理办法》《上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等要求，就公司在任独立董事陈收先生、郭月梅女士、高国垒先生的独立性 情况进行评估并出具如下专项意见： 根据公司独立董事自查及其在公司的履职情况，董事会认为，公司在任独立 董事均能够胜任独立董事的职责要求，未在公司担任除独立董事以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在妨 碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号—创业 板上市公司规范运作》等法律、法规、规范性文件及《公司章程》《独立董事工 作制度》中关于独立董事的任职资格及独立性的相关要求。 爱尔眼科医院集团股份有限公司董事会 关于独立董事独立性情况的专项意见 ...

独立董事2024 年年度述职报告 爱尔眼科医院集团股份有限公司 独立董事 2024 年年度述职报告 陈 收 本人作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"或"公司"） 的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章的规定和要 求，在 2024 年工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认 真审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事 及各专门委员会的作用。现向董事会和股东大会提交 2024 年年度述职报告，对 履行职责的情况进行说明，请予审查。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人陈收，中国国籍，中共党员，博士研究生，教授。历任湖南大学国际商 学院、工商管理学院副院长、院长，湖南大学校长助理、副校长。现任湖南大学 工商管理学院教授。2019 年 11 月起任爱尔眼科独立董事。 （二）不存在影响独立性的情况 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公 ...

独立董事2024 年年度述职报告 爱尔眼科医院集团股份有限公司 独立董事 2024 年年度述职报告 郭月梅 本人作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"或"公司"） 的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章的规定和要 求，在2024年工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认真 审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事及 各专门委员会的作用。现向董事会和股东大会提交2024年年度述职报告，对履行 职责的情况进行说明，请予审查。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人郭月梅，澳大利亚莫纳什大学税法博士，中南财经政法大学财政税务学 院二级教授，博士生导师，高级会计师，澳大利亚注册会计师。2019 年 12 月起 任爱尔眼科独立董事。兼任楚天智能、力源信息独立董事。 （二）不存在影响独立性的情况 独立董事2024 年年度述职报告 2024 年本人亲自出席了应出席的董事会、专门委员 ...